📰 Stroke Statistics News
Page 17 - Stroke Statistics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Stroke Statistics. Real-time updates on events, politics, business and more.
May 27, 2021
Global Peptide Therapeutics Market Industry News, Development Opportunities & Challenges
May 25, 2021
An Eye Exam Could Reveal These Unexpected Health Conditions That Visit to the Optometrist Could Reveal More Than Just Information Related to Your Eyes By Newsweek AMPLIFY Pexels Your health should be one of your top priorities, especially during these times. When was the last time you had an eye exam? If its been a year or longer, you might want to think about booking that appointment. A full eye exam should be part of your regular wellness routine—like getting a physical check-up or going...
May 15, 2021
Share: Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels Amarin to Webcast Discussion of Data Presented at ACC.21 Monday, May 17, 2021 at 4:30 p.m., Eastern Time DUBLIN, Ireland and BRIDGEWATER, N.J., May 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT ® ...
April 29, 2021
Share: Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Recedes Expenses Managed in Q1 2021 to Minimize Operating Loss Despite Revenue Impact of COVID-19 and Other Factors Management to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), toda...
April 22, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and ... Amarin Corporation plcApril 22, 2021 GMT VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication 1,2, VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 20...
April 19, 2021
American Heart Association The American Heart Association, the world’s leading voluntary organization dedicated to a world of longer, healthier lives, is investing $20 million to study ways to prevent high blood pressure, particularly in underrepresented populations. Applications are now being accepted for coordinated submission of three to five research centers and a coordinating center that will be funded through this fast-track initiative. Letters of intent are required and due by Friday, ...
April 17, 2021
Message : Required fields Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Pati...
April 8, 2021
Tsunami of Chronic Health Conditions Expected, Research & Health Care Disrupted By: Journal Reports, AHA A tsunami of chronic health conditions as a result of the SARS-CoV-2 pandemic, especially cardiometabolic disease, may produce an enormous wave of death and disability that demands immediate, comprehensive strategies. In addition, COVID-19 has disrupted cardiovascular science and medicine, yet it presents opportunities to transform and create novel approaches that can yield new successes. ...
April 7, 2021
Expert calls for swift action to avoid chronic health conditions caused by COVID-19 A tsunami of chronic health conditions as a result of the SARS-CoV-2 pandemic, especially cardiometabolic disease, may produce an enormous wave of death and disability that demands immediate, comprehensive strategies. In addition, COVID-19 has disrupted cardiovascular science and medicine, yet it presents opportunities to transform and create novel approaches that can yield new successes. These are the opinions ...
April 7, 2021
Tsunami of Chronic Health Conditions Expected Due to COVID-19 Disruption of Healthcare COVID-19 disrupted all aspects of science and medicine and unmasked striking disparities and opportunities for transformation April 6, 2021 — A tsunami of chronic health conditions as a result of the COVID-19 (SARS-CoV-2) pandemic, especially cardiometabolic disease, may produce an enormous wave of death and disability that demands immediate, comprehensive strategies. In addition, COVID-19 has disrupted car...